HRP20170102T1 - Antioksidantni modulatori upale: c17-homologiranih derivata oleanolne kiseline - Google Patents
Antioksidantni modulatori upale: c17-homologiranih derivata oleanolne kiseline Download PDFInfo
- Publication number
- HRP20170102T1 HRP20170102T1 HRP20170102TT HRP20170102T HRP20170102T1 HR P20170102 T1 HRP20170102 T1 HR P20170102T1 HR P20170102T T HRP20170102T T HR P20170102TT HR P20170102 T HRP20170102 T HR P20170102T HR P20170102 T1 HRP20170102 T1 HR P20170102T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- substituted
- compound according
- carbon
- disease
- Prior art date
Links
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical class C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 title 1
- 206010061218 Inflammation Diseases 0.000 title 1
- 239000003963 antioxidant agent Substances 0.000 title 1
- 230000003078 antioxidant effect Effects 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 22
- 125000002252 acyl group Chemical group 0.000 claims 10
- 125000004423 acyloxy group Chemical group 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000004429 atom Chemical group 0.000 claims 6
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 5
- 229910019142 PO4 Inorganic materials 0.000 claims 5
- 125000003368 amide group Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 239000010452 phosphate Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 125000002015 acyclic group Chemical group 0.000 claims 4
- 125000003282 alkyl amino group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000004122 cyclic group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000006323 alkenyl amino group Chemical group 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims 3
- 125000006319 alkynyl amino group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims 3
- 125000001769 aryl amino group Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims 3
- 125000005241 heteroarylamino group Chemical group 0.000 claims 3
- 239000003607 modifier Substances 0.000 claims 3
- -1 1,3-dioxoisoindolin-2-yl Chemical group 0.000 claims 2
- 239000004215 Carbon black (E152) Substances 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 125000005210 alkyl ammonium group Chemical group 0.000 claims 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 229930195733 hydrocarbon Natural products 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 229910052740 iodine Inorganic materials 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 229910052710 silicon Inorganic materials 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000005035 acylthio group Chemical group 0.000 claims 1
- 125000005136 alkenylsulfinyl group Chemical group 0.000 claims 1
- 125000005137 alkenylsulfonyl group Chemical group 0.000 claims 1
- 125000005108 alkenylthio group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000005277 alkyl imino group Chemical group 0.000 claims 1
- 125000005103 alkyl silyl group Chemical group 0.000 claims 1
- 125000005134 alkynylsulfinyl group Chemical group 0.000 claims 1
- 125000005139 alkynylsulfonyl group Chemical group 0.000 claims 1
- 125000005109 alkynylthio group Chemical group 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 claims 1
- 125000005110 aryl thio group Chemical group 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- HNNOXINYKDAQHH-UHFFFAOYSA-N cyanato-N-diazophosphonamidic acid Chemical compound C(#N)OP(=O)(O)N=[N+]=[N-] HNNOXINYKDAQHH-UHFFFAOYSA-N 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 125000005150 heteroarylsulfinyl group Chemical group 0.000 claims 1
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 claims 1
- 125000005368 heteroarylthio group Chemical group 0.000 claims 1
- 150000002430 hydrocarbons Chemical class 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 1
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 125000003441 thioacyl group Chemical group 0.000 claims 1
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 210000002229 urogenital system Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
- C07C53/16—Halogenated acetic acids
- C07C53/18—Halogenated acetic acids containing fluorine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/36—Compounds containing oxirane rings with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
Claims (19)
1. Spoj, naznačen time što ima formulu:
[image]
,
gdje:
Y je alkandiil(C≤8), alkendiil(C≤8), alkindiil(C≤8), ili supstituirana verzija bilo koje od tih skupina;
Ra je:
vodik, hidroksi, halogen, amino, nitro, cijano, azido, fosfat, 1,3-dioksoizoindolin-2-il, merkapto ili silil; ili
alkil(C≤12), alkenil(C≤12), alkinil(C≤12), aril(C≤12), aralkil(C≤12), heteroaril(C≤12), heteroaralkil(C≤12), acil(C≤12), alkoksi(C≤12), alkeniloksi(C≤12), alkiniloksi(C≤12), ariloksi(C≤12), aralkoksi(C≤12), heteroariloksi(C≤12), heteroaralkoksi(C≤12), aciloksi(C≤12), alkilamino(C≤12), dialkilamino(C≤12), alkenilamino(C≤12), alkinilamino(C≤12), arilamino(C≤12), aralkilamino(C≤12), heteroarilamino(C≤12), heteroaralkilamino(C≤12), alkilsulfonilamino(C≤12), amido(C≤12), alkiltio(C≤12), alkeniltio(C≤12), alkiniltio(C≤12), ariltio(C≤12), aralkiltio(C≤12), heteroariltio(C≤12), heteroaralkiltio(C≤12), aciltio(C≤12), tioacil(C≤12), alkilsulfonil(C≤12), alkenilsulfonil(C≤12), alkinilsulfonil(C≤12), arilsulfonil(C≤12), aralkilsulfony(C≤12), heteroarilsulfonil(C≤12), heteroaralkilsulfonil(C≤12), alkilsulfinil(C≤12), alkenilsulfinil(C≤12), alkinilsulfinil(C≤12), arilsulfinil(C≤12), aralkilsulinil(C≤12), heteroarilsulfinil(C≤12), hetero-aralkilsulfinil(C≤12), alkilfosfonil(C≤12), alkil-fosfat(C≤12), dialkil-fosfat(C≤12), alkilamonij(C≤12), alkilsulfonij(C≤12), alkilsilil(C≤12), ili supstituirana verzija bilo koje od tih skupina; ili
Y i Ra tvore tro- do sedmeročlani prsten, tako da su Y i Ra dodatno međusobno povezani preko jednog ili više od -O- i alkandiila(C1-5), gdje je Y dodatno -CH-, a Ra je -CH2-; ili
Y, Ra i ugljik broj 13, 17 i 18 tvore prsten, tako da je Ra vezan na ugljik 13, gdje je Y alkandiil(C=1) ili supstituirani alkandiil(C=1), a Ra je -O-;
gdje se termin "alkenil", kada se upotrebljava bez modifikatora "supstituirani", odnosi na jednovalentnu skupinu s nearomatskim atomom ugljika kao mjestom vezanja, s nerazgranatom, razgranatom, ciklo, cikličkom ili acikličkom strukturom, najmanje jednom nearomatskom dvostrukom vezom ugljik-ugljik, bez trostrukih veza ugljik-ugljik, te bez atoma koji nisu ugljik i vodik;
gdje se termin "supstituirani alkenil" odnosi na jednovalentnu skupinu s nearomatskim atomom ugljika kao mjestom vezanja, najmanje jednom nearomatskom dvostrukom vezom ugljik-ugljik, bez trostrukih veza ugljik-ugljik, s nerazgranatom, razgranatom, ciklo, cikličkom ili acikličkom strukturom, gdje se najmanje jedan atom neovisno bira iz skupine koju čine N, O, F, Cl, Br, I, Si, P i S;
gdje se termin "alkinil", kada se upotrebljava bez modifikatora "supstituirani", odnosi na jednovalentnu skupinu s nearomatskim atomom ugljika kao mjestom vezanja, s nerazgranatom, razgranatom, ciklo, cikličkom ili acikličkom strukturom, najmanje jednom trostrukom vezom ugljik-ugljik, te bez atoma koji nisu ugljik i vodik;
gdje se termin "supstituirani alkinil" odnosi na jednovalentnu skupinu s nearomatskim atomom ugljika kao mjestom vezanja i najmanje jedna trostrukom vezom ugljik-ugljik, s nerazgranatom, razgranatom, ciklo, cikličkom ili acikličkom strukturom, gdje se najmanje jedan atom neovisno bira iz skupine koju čine N, O, F, Cl, Br, I, Si, P i S;
gdje se termin "aril", kada se upotrebljava bez modifikatora "supstituirani", odnosi na jednovalentnu skupinu s aromatskim atomom ugljika kao mjestom vezanja, gdje navedeni atom ugljika čini dio šesteročlane aromatske prstenaste strukture, gdje su svi atomi u prstenu ugljici, te gdje jednovalentna skupina ne sadrži atome koji nisu ugljik i vodik;
gdje termin "alkilna skupina" uključuje alkilne skupine koje mogu sadržavati jednu ili više cikloalkilnih komponenti;
gdje tražene ugljikovodične komponente u alkandiilnim, alkendiilnim i alkindiilnim skupinama uključuju ugljikovodične komponente koje mogu sadržavati jedan ili više karbocikličkih dijelova;
gdje alkilni dijelovi u alkoksi, alkilamino, alkilimino, alkiltio, alkilsulfonilnim, alkilsulfinilnim, alkilamonijskim i alkilsulfonijskim skupinama uključuju alkilne dijelove koji mogu sadržavati jednu ili više cikloalkilnih komponenti;
ili njegova farmaceutski prihvatljiva sol ili tautomer.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je dodatno definiran kao:
[image]
,
gdje:
Y je alkandiil(C≤5) ili supstituirani alkandiil(C≤5);
Ra je:
vodik, hidroksi, halogen, amino, fosfat, 1,3-dioksoizoindolin-2-il ili cijano; ili
alkil(C≤12), alkenil(C≤12), alkinil(C≤12), aril(C≤12), aralkil(C≤12), heteroaril(C≤12), heteroaralkil(C≤12), acil(C≤12), alkoksi(C≤12), alkeniloksi(C≤12), alkiniloksi(C≤12), ariloksi(C≤12), aralkoksi(C≤12), heteroariloksi(C≤12), heteroaralkoksi(C≤12), aciloksi(C≤12), alkilamino(C≤12), dialkilamino(C≤12), alkenilamino(C≤12), alkinilamino(C≤12), arilamino(C≤12), aralkilamino(C≤12), heteroarilamino(C≤12), heteroaralkilamino(C≤12), alkilsulfonilamino(C≤12), amido(C≤12), arilsulfonil(C≤12), arilsulfinil(C≤12), alkil-fosfat(C≤12), dialkil-fosfat(C≤12), ili supstituirana verzija bilo koje od tih skupina; ili
Y i Ra tvore tro- do peteročlani prsten, tako da su Y i Ra dodatno međusobno povezani preko jednog ili više od -O- i alkandiila(C1-3), gdje je Y dodatno -CH-, a Ra je -CH2-;
ili njegova farmaceutski prihvatljiva sol ili tautomer.
3. Spoj u skladu s patentnim zahtjevom 2, naznačen time što Y predstavlja -CH2-; i/ili
Ra predstavlja hidroksi, cijano, acil(C≤8), supstituirani acil(C≤8), aciloksi(C≤8), supstituirani aciloksi(C≤8), amido(C≤8) ili supstituirani amido(C≤8);
ili njegova farmaceutski prihvatljiva sol ili tautomer.
4. Spoj u skladu s patentnim zahtjevom 2, naznačen time što je dodatno definiran kao:
[image]
,
gdje je Ra hidroksi, cijano, acil(C≤8), supstituirani acil(C≤8), aciloksi(C≤8) ili supstituirani aciloksi(C≤8), ili njegova farmaceutski prihvatljiva sol ili tautomer.
5. Spoj u skladu s patentnim zahtjevom 2, naznačen time što je dodatno definiran kao:
[image]
,
gdje je Ra hidroksi, cijano, acil(C≤8), supstituirani acil(C≤8), aciloksi(C≤8) ili supstituirani aciloksi(C≤8), ili njegova farmaceutski prihvatljiva sol ili tautomer.
6. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je Y -C(OH)HCH2-.
7. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačen time što je Ra -OH, -Cl, -Br ili -H.
8. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što je Ra -OH.
9. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što:
Ra je acil(C1-3) ili supstituirani acil(C1-3); ili
Ra je aciloksi(C1-8) ili supstituirani aciloksi(C1-3).
10. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačen time što je Ra alkilamino(C≤12), dialkilamino(C≤12), alkenilamino(C≤12), alkinilamino(C≤12), arilamino(C≤12), aralkilamino(C≤12), heteroarilamino(C≤12), heteroaralkilamino(C≤12), alkilsulfonilamino(C≤12) ili amido(C≤12), ili supstituirana verzija bilo koje od tih skupina.
11. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je dodatno definiran kao:
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
.
12. Spoj, naznačen time što ima formulu:
[image]
.
13. Farmaceutski pripravak, naznačen time što kao aktivni sastojak sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1-12, kao i farmaceutski prihvatljivu podlogu.
14. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-12, naznačen time što je namijenjen upotrebi kao farmaceutsko sredstvo.
15. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-12, naznačen time što je namijenjen upotrebi u liječenju raka, primjerice karcinoma, sarkoma, limfoma, leukemije, melanoma, mezotelioma, multiplog mijeloma ili seminoma i/ili kada je u pitanju rak mokraćnog mjehura, krvi, kostiju, na mozgu, dojke, središnjeg živčanog sustava, kolona, endometrija, jednjaka, genitourinarnog sustava, glave, grkljana, jetre, pluća, vrata, jajnika, gušterače, prostate, slezene, tankog crijeva, debelog crijeva, želuca ili testisa.
16. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-12, naznačen time što je namijenjen upotrebi u liječenju bolesti ili stanja s upalnom komponentom kod subjekta, primjerice gdje je bolest lupus, reumatoidni artritis, upalna crijevna bolest, kardiovaskularna bolest, dijabetes, metabolički sindrom, metabolički sindrom (sindrom X), psorijaza, akne ili atopični dermatitis.
17. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-12, naznačen time što je namijenjen upotrebi u liječenju neurodegenerativne bolesti kod subjekta, primjerice gdje je bolest Parkinsonova bolest, Alzheimerova bolest, multipla skleroza (MS), Huntingtonova bolest ili amiotrofna lateralna skleroza.
18. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-12, naznačen time što je namijenjen upotrebi u liječenju bolesti bubrega (RKD) kod subjekta.
19. Komplet, naznačen time što sadrži:
spoj u skladu s bilo kojim od patentnih zahtjeva 1-12; i
upute, koje sadrže jedan ili više oblika informacija, koje se bira iz skupine koju čine indikacije bolesnog stanja za koje spoj treba primijeniti, informacije o spremanju spoja, informacije o doziranju i upute o tome kako primijeniti spoj.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4636608P | 2008-04-18 | 2008-04-18 | |
US11129408P | 2008-11-04 | 2008-11-04 | |
EP09732769.6A EP2271658B1 (en) | 2008-04-18 | 2009-04-20 | Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives |
PCT/US2009/041176 WO2009129548A1 (en) | 2008-04-18 | 2009-04-20 | Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20170102T1 true HRP20170102T1 (hr) | 2017-03-24 |
Family
ID=40852224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20170102TT HRP20170102T1 (hr) | 2008-04-18 | 2017-01-23 | Antioksidantni modulatori upale: c17-homologiranih derivata oleanolne kiseline |
Country Status (28)
Country | Link |
---|---|
US (3) | US7943778B2 (hr) |
EP (1) | EP2271658B1 (hr) |
JP (2) | JP5588966B2 (hr) |
KR (2) | KR20110010611A (hr) |
CN (2) | CN104250280A (hr) |
AU (2) | AU2009237581C1 (hr) |
BR (1) | BRPI0911422B8 (hr) |
CA (1) | CA2721666C (hr) |
CO (1) | CO6311107A2 (hr) |
CY (1) | CY1118475T1 (hr) |
DK (1) | DK2271658T3 (hr) |
EA (1) | EA020156B1 (hr) |
ES (1) | ES2613964T3 (hr) |
HK (2) | HK1152713A1 (hr) |
HR (1) | HRP20170102T1 (hr) |
HU (1) | HUE033288T2 (hr) |
IL (1) | IL208759B (hr) |
LT (1) | LT2271658T (hr) |
ME (1) | ME02751B (hr) |
MX (1) | MX2010011439A (hr) |
NZ (1) | NZ588711A (hr) |
PL (1) | PL2271658T3 (hr) |
PT (1) | PT2271658T (hr) |
RS (1) | RS55631B1 (hr) |
SI (1) | SI2271658T1 (hr) |
TW (1) | TWI584808B (hr) |
WO (1) | WO2009129548A1 (hr) |
ZA (1) | ZA201007589B (hr) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
CN102886045A (zh) | 2005-02-03 | 2013-01-23 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
KR101354828B1 (ko) | 2005-11-04 | 2014-02-18 | 와이어쓰 엘엘씨 | mTOR 저해자, 헤르셉틴, 및/또는 HKI-272의항신생물성 조합 |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
MX356760B (es) | 2008-01-11 | 2018-06-12 | Dartmouth College | Triterpenoides sinteticos y metodos de uso en el tratamiento de enfermedad. |
US7915402B2 (en) | 2008-04-18 | 2011-03-29 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring |
CN102066397B (zh) | 2008-04-18 | 2013-09-11 | 里亚塔医药公司 | 包含抗炎症药效团的化合物以及使用方法 |
AU2009237579C1 (en) | 2008-04-18 | 2016-05-12 | Reata Pharmaceuticals Holdings, LLC | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
WO2009129548A1 (en) | 2008-04-18 | 2009-10-22 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives |
US8071632B2 (en) | 2008-04-18 | 2011-12-06 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
EP3135285B1 (en) | 2008-06-17 | 2018-08-15 | Wyeth LLC | Antineoplastic combinations containing hki-272 and vinorelbine |
EP2309860B1 (en) * | 2008-07-22 | 2014-01-08 | Trustees of Dartmouth College | Monocyclic cyanoenones and methods of use thereof |
EP2326329B1 (en) | 2008-08-04 | 2017-01-11 | Wyeth LLC | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
DK3000467T3 (da) | 2009-04-06 | 2023-03-27 | Wyeth Llc | Behandling med neratinib mod brystkræft |
PL2558105T3 (pl) | 2010-04-12 | 2020-04-30 | Reata Pharmaceuticals, Inc. | Metylowany bardoksolon do leczenia otyłości |
WO2011153315A1 (en) * | 2010-06-04 | 2011-12-08 | Bristol-Myers Squibb Company | Modified c-3 betulinic acid derivatives as hiv maturation inhibitors |
EP2576586B1 (en) * | 2010-06-04 | 2015-08-12 | Bristol-Myers Squibb Company | C-28 amides of modified c-3 betulinic acid derivatives as hiv maturation inhibitors |
EA025568B1 (ru) | 2010-12-17 | 2017-01-30 | Рита Фармасьютикалз, Инк. | Пиразолильные и пиримидинильные трициклические еноны в качестве антиоксидантных модуляторов воспаления |
EA026847B1 (ru) | 2011-03-11 | 2017-05-31 | Рита Фармасьютикалз, Инк. | C4-монометилтритерпеноидные производные и способы их применения |
PE20150160A1 (es) | 2012-04-27 | 2015-02-19 | Reata Pharmaceuticals Inc | Derivados de 2,2-difluoropropionamida de bardoxolona metilo, formas polimorficas y metodos de uso de los mismos |
US8921419B2 (en) | 2012-05-08 | 2014-12-30 | Trustees Of Dartmouth College | Triterpenoids and compositions containing the same |
US8981144B2 (en) | 2012-05-08 | 2015-03-17 | Trustees Of Dartmouth College | Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof |
WO2013188818A1 (en) | 2012-06-15 | 2013-12-19 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
UY35023A (es) * | 2012-09-10 | 2014-03-31 | Reata Pharmaceuticals Inc | Derivados c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso |
DK2892911T3 (en) * | 2012-09-10 | 2017-10-23 | Reata Pharmaceuticals Inc | C17 heteroaryl derivatives of oleanolic acid and methods of use thereof |
WO2014040052A2 (en) * | 2012-09-10 | 2014-03-13 | Abbvie Inc. | Glycyrrhetinic acid derivatives and methods of use thereof |
US9278912B2 (en) | 2012-09-10 | 2016-03-08 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
CN102861037B (zh) * | 2012-10-26 | 2014-04-16 | 吴俊华 | Gypensapogenin B在治疗动脉粥样硬化药物中的应用 |
CN103800902A (zh) * | 2012-11-14 | 2014-05-21 | 中国药科大学 | 含有齐墩果酸的药物组合物及其医药用途 |
WO2014091467A2 (en) * | 2012-12-16 | 2014-06-19 | Mahesh Kandula | Compositions and methods for the treatment of autoimmune diseases and inflammation |
TW201514192A (zh) | 2013-03-19 | 2015-04-16 | Daiichi Sankyo Co Ltd | 萜類衍生物 |
TW201936625A (zh) | 2013-04-24 | 2019-09-16 | 美商艾伯維有限公司 | 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法 |
EA201690456A1 (ru) | 2013-08-23 | 2016-06-30 | Рита Фармасьютикалз, Инк. | Способы лечения и предотвращения эндотелиальной дисфункции с применением бардоксолона метила или его аналогов |
US9896475B2 (en) | 2014-08-26 | 2018-02-20 | Trustees Of Dartmouth College | Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole |
US10189791B2 (en) | 2014-08-26 | 2019-01-29 | Trustees Of Dartmouth College | Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole |
ES2770772T3 (es) | 2014-09-10 | 2020-07-03 | Daiichi Sankyo Co Ltd | Composición farmacéutica de liberación sostenida para el tratamiento y prevención de enfermedades oculares |
KR20170117092A (ko) | 2015-02-12 | 2017-10-20 | 리아타 파마슈티컬즈, 아이엔씨. | 항산화 염증 조절제로서의 이미다졸릴 트리사이클릭 에논 |
CA2998681C (en) | 2015-09-23 | 2024-02-06 | Reata Pharmaceuticals, Inc. | C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses |
KR102475130B1 (ko) * | 2016-03-31 | 2022-12-07 | (주)아모레퍼시픽 | 펜타사이클릭 트리터펜 카페익 액씨드 에스터를 포함하는 피부 보습 또는 피부 미백용 조성물 |
BR112019009256A2 (pt) | 2016-11-08 | 2019-07-16 | Reata Pharmaceuticals Inc | métodos para tratar síndrome de alport usando bardoxolona metil ou análogos do mesmo |
TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制RORγ及其他用途的嘧啶三環烯酮衍生物 |
CN111417384A (zh) | 2017-09-14 | 2020-07-14 | 菲尼克斯生物技术公司 | 用于治疗神经系统病况的方法和改进的神经保护性组合物 |
IL285232B (en) | 2017-09-14 | 2022-07-01 | Phoenix Biotechnology Inc | Preparations containing oleandrin for the treatment of viral infection |
US10137138B1 (en) | 2018-05-29 | 2018-11-27 | King Saud University | Sulfonylurea derivatives of oleanolic acid |
WO2020163642A1 (en) * | 2019-02-07 | 2020-08-13 | Ardelyx, Inc. | Glycyrrhetinic acid derivatives for use in treating hyperkalemia |
PE20221662A1 (es) * | 2019-12-19 | 2022-10-26 | Reata Pharmaceuticals Inc | Triterpenoides sinteticos con sustituyentes a base de nitrogeno en c-17 y metodos de uso de los mismos |
CN111205346B (zh) * | 2020-02-10 | 2022-01-28 | 中国药科大学 | 齐墩果酸的衍生物及其医药用途 |
KR20220151038A (ko) | 2020-03-31 | 2022-11-11 | 피닉스 바이오테크놀러지 인코포레이티드. | 코로나바이러스 감염 예방를 위한 조성물 |
EP4009981B1 (en) | 2020-03-31 | 2023-08-16 | Phoenix Biotechnology, Inc. | Method and compositions for treating coronavirus infection |
WO2021202720A1 (en) * | 2020-04-01 | 2021-10-07 | Fronthera U.S. Pharmaceuticals Llc | Use of triterpenoid nrf2 inhibitors |
MX2022014034A (es) | 2020-05-09 | 2023-01-11 | Reata Pharmaceuticals Holdings Llc | Métodos para tratar covid-19 con el uso de bardoxolona metilo o análogos de esta. |
EP4259155A1 (en) | 2020-12-11 | 2023-10-18 | Reata Pharmaceuticals Holdings, LLC | Synthetic triterpenoids for use in therapy |
TW202245795A (zh) * | 2021-01-18 | 2022-12-01 | 美商瑞塔醫藥有限責任公司 | 合成之熊果酸衍生物及其使用方法 |
CN115626947A (zh) * | 2022-09-27 | 2023-01-20 | 中山大学 | 五环三萜类天然产物的合成及其应用 |
CN115501237B (zh) * | 2022-10-27 | 2023-09-05 | 五邑大学 | 齐墩果酸衍生物在制备抑菌药物中的应用 |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1435622A (en) | 1973-11-07 | 1976-05-12 | Biorex Laboratories Ltd | Erythrodiol derivatives |
JPS5555153U (hr) | 1978-10-06 | 1980-04-14 | ||
US4395423A (en) | 1978-10-10 | 1983-07-26 | Sterling Drug Inc. | Polycyclic cyanoketones |
US4634208A (en) | 1983-01-31 | 1987-01-06 | Amp Incorporated | Electrical plug connector and method of terminating a cable therewith |
US4526988A (en) | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
DE3321117A1 (de) | 1983-06-10 | 1984-12-13 | Siemens AG, 1000 Berlin und 8000 München | Magnetische multipolanordnung n-ter ordnung |
IL77133A (en) | 1984-12-04 | 1991-01-31 | Lilly Co Eli | Antineoplastic pharmaceutical compositions containing pentofuranoside derivatives,some new such compounds and their preparation |
US4635208A (en) | 1985-01-18 | 1987-01-06 | Hewlett-Packard Company | Computer-aided design of systems |
US4636308A (en) | 1985-06-13 | 1987-01-13 | Summers Don D | Method and apparatus for reclaiming drilling fluids from undesirable solids in a drilling operation |
US4636608A (en) | 1985-11-15 | 1987-01-13 | Benteler Corporation | Laser contour cut door beams |
US5013649A (en) | 1986-07-01 | 1991-05-07 | Genetics Institute, Inc. | DNA sequences encoding osteoinductive products |
IL84842A0 (en) | 1986-12-24 | 1988-06-30 | Lilly Co Eli | Immunoglobulin conjugates |
ZA891076B (en) | 1988-02-16 | 1990-10-31 | Lilly Co Eli | 2',3'-dideoxy-2',2'-difluoronucleosides |
US5443826A (en) | 1988-08-02 | 1995-08-22 | Borody; Thomas J. | Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli |
US5064823A (en) | 1988-08-24 | 1991-11-12 | Research Triangle Institute | Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers |
CA2004695C (en) | 1988-12-12 | 1999-08-10 | Rosanne Bonjouklian | Phospholipid nucleosides |
WO1991015498A2 (en) | 1990-04-04 | 1991-10-17 | Nycomed Imaging As | Nucleoside derivatives |
SE502569C2 (sv) | 1991-05-31 | 1995-11-13 | British Tech Group | Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit |
US5606048A (en) | 1992-06-22 | 1997-02-25 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
YU43193A (sh) | 1992-06-22 | 1997-01-08 | Eli Lilly And Company | 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi |
US5426183A (en) | 1992-06-22 | 1995-06-20 | Eli Lilly And Company | Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
US5401838A (en) | 1992-06-22 | 1995-03-28 | Eli Lilly And Company | Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
UA41261C2 (uk) | 1992-06-22 | 2001-09-17 | Елі Ліллі Енд Компані | Спосіб одержання збагачених бета-аномером нуклеозидів |
DE4308042C2 (de) | 1993-03-13 | 2000-10-12 | Alstom Energy Syst Gmbh | Wälzmühle |
US6025395A (en) | 1994-04-15 | 2000-02-15 | Duke University | Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders |
US5972703A (en) | 1994-08-12 | 1999-10-26 | The Regents Of The University Of Michigan | Bone precursor cells: compositions and methods |
US5599795A (en) | 1994-08-19 | 1997-02-04 | Mccann; Michael | Method for treatment of idiopathic inflammatory bowel disease (IIBD) |
US5521294A (en) | 1995-01-18 | 1996-05-28 | Eli Lilly And Company | 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides |
WO1998000173A2 (en) | 1996-07-03 | 1998-01-08 | Pharmacia & Upjohn Company | Targeted drug delivery using sulfonamide derivatives |
AU720451B2 (en) | 1997-01-24 | 2000-06-01 | Conpharma As | Gemcitabine derivatives |
US20050276836A1 (en) | 1997-06-11 | 2005-12-15 | Michelle Wilson | Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents |
US5965119A (en) | 1997-12-30 | 1999-10-12 | Enzon, Inc. | Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents |
US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
US6369101B1 (en) | 1999-02-26 | 2002-04-09 | Regents Of The University Of Minnesota | Therapeutic method to treat herpes virus infection |
US6485756B1 (en) | 1999-04-06 | 2002-11-26 | Collaborative Technologies, Inc. | Stable, homogeneous natural product extracts containing polar and apolar fractions |
PT1178952E (pt) | 1999-05-14 | 2007-12-04 | Univ California | Novos moduladores da interleucina-1 e do factor alfa de necrose tumoral, síntese dos referidos moduladores e métodos de utilização dos referidos moduladores |
EP1105730B1 (en) | 1999-06-25 | 2008-01-23 | Roche Diagnostics Operations, Inc. | Enzyme inhibition immunoassay |
US6649654B1 (en) | 1999-11-23 | 2003-11-18 | The Regents Of The University Of California | Methods for identifying and using IKK inhibitors |
JP2001240573A (ja) * | 2000-03-01 | 2001-09-04 | Meiji Seika Kaisha Ltd | トリテルペン誘導体及び肝疾患治療剤 |
WO2002003996A1 (en) | 2000-07-12 | 2002-01-17 | RAJKUMAR, Sujatha | Use of dammarane-type tritepenoid saporins |
AU2001294959A1 (en) | 2000-09-29 | 2002-04-08 | Robert M. Carlson | Triterpenes having antibacterial activity |
US6951847B2 (en) | 2000-09-29 | 2005-10-04 | Regents Of The University Of Minnesota | Methods of treating fungal infections using lupeol |
EP1322661A1 (en) | 2000-09-29 | 2003-07-02 | Regents Of The University Of Minnesota | Triterpenes having fungicidal activity against yeast |
US6878751B1 (en) | 2000-10-19 | 2005-04-12 | Imperial College Of Science Technology And Medicine | Administration of resveratrol to treat inflammatory respiratory disorders |
US7435755B2 (en) | 2000-11-28 | 2008-10-14 | The Trustees Of Dartmouth College | CDDO-compounds and combination therapies thereof |
CA2430454A1 (en) | 2000-11-28 | 2002-06-20 | Board Of Regents, The University Of Texas System | Cddo-compounds and combination therapies thereof |
AU2002308701A1 (en) | 2001-05-14 | 2002-11-25 | University Of Maryland, Baltimore | Novel alanine transaminase enzyme and methods of use |
CN1240102C (zh) | 2001-10-31 | 2006-02-01 | 东芝照明技术株式会社 | 灯泡形荧光灯和照明器具 |
CN1615131A (zh) | 2001-11-23 | 2005-05-11 | 中外制药株式会社 | 肿瘤靶向酶的鉴定方法 |
US7176237B2 (en) | 2002-01-15 | 2007-02-13 | The Trustees Of Dartmouth College | Tricyclic-bis-enone derivatives and methods of use thereof |
EP1465914B1 (en) | 2002-01-18 | 2008-12-17 | Regents Of The University Of Minnesota | Triterpene quaternary salts as biologically active surfactants |
AU2003303128A1 (en) * | 2002-05-13 | 2004-08-13 | Trustees Of Dartmouth College | Inhibitors and methods of use thereof |
EP1567169A4 (en) | 2002-11-04 | 2009-10-21 | Xenoport Inc | GEMCITABINE PROMOTERS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES THEREOF |
US20050014730A1 (en) | 2003-04-02 | 2005-01-20 | Carlson Robert M. | Anti-fungal formulation of triterpene and essential oil |
WO2005042002A2 (en) | 2003-10-30 | 2005-05-12 | Entelos, Inc. | Treatment of rhematoid arthritis with flip antagonists |
US8288439B2 (en) | 2003-11-04 | 2012-10-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for the inhibition of HIV-1 replication |
ZA200604862B (en) | 2003-12-22 | 2007-10-31 | Alcon Inc | Agents for treatment of glaucomatous retinopathy and optic neuropathy |
US20060258752A1 (en) | 2004-02-12 | 2006-11-16 | Vander Jagt David L | Method and compounds for cancer treatment utilizing NFkB as a direct or ultimate target for small molecule inhibitors |
JP2005314381A (ja) | 2004-03-30 | 2005-11-10 | Anges Mg Inc | 増殖性腎疾患の予防・治療・改善剤 |
EP1811840B1 (en) | 2004-09-07 | 2016-04-13 | May Sung Mak | Anti-tumor compounds with angeloyl groups |
US7714726B2 (en) | 2005-05-06 | 2010-05-11 | Dominic M. Kotab | Semi-transparent RFID tags |
JP2006347952A (ja) * | 2005-06-16 | 2006-12-28 | Yoshihiro Futamura | リパーゼ活性化作用を呈するアントラキノン誘導体、それからなる抗肥満薬、食品製剤及び化粧品 |
CA2614110A1 (en) | 2005-07-01 | 2007-01-11 | The Johns Hopkins University | Compositions and methods for the treatment or prevention of disorders relating to oxidative stress |
DE102005041613A1 (de) | 2005-09-01 | 2007-03-08 | Ergonex Pharma Gmbh | Pharmazeutische Zusammensetzungen zur Behandlung von Karzinoid-Syndrom |
JP5558719B2 (ja) | 2005-12-12 | 2014-07-23 | モサメディックス・ビー.ブイ. | 治療および診断におけるプレターゲッティングに適したアネキシン誘導体 |
WO2007112043A2 (en) | 2006-03-23 | 2007-10-04 | Advanced Life Sciences Inc. | Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin |
US20070249561A1 (en) | 2006-04-25 | 2007-10-25 | Taylor Bradley K | Pharmacological method for treatment of neuropathic pain |
CA2653726C (en) | 2006-06-27 | 2015-05-12 | Wellington Laboratories Inc. | Glycyrrhetinic acid derivatives |
CN101117348B (zh) * | 2006-08-01 | 2010-12-29 | 浙江海正药业股份有限公司 | A环和c环多氧化取代的五环三萜及其制备方法和用途 |
JP2008110962A (ja) | 2006-08-02 | 2008-05-15 | Santen Pharmaceut Co Ltd | Nrf2活性化物質を有効成分として含む角結膜障害の予防または治療剤 |
WO2008016095A1 (fr) | 2006-08-02 | 2008-02-07 | Santen Pharmaceutical Co., Ltd. | REMÈDE PRÉVENTIF OU CURATIF POUR LES KÉRATOCONJONCTIVITES CONTENANT UN ACTIVATEUR DE Nrf2 EN TANT QUE MATIÈRE ACTIVE |
WO2008063318A2 (en) | 2006-10-12 | 2008-05-29 | The Texas A & M University System And Safe Et Al | Betulinic acid, derivatives and analogs thereof and uses therefor |
WO2008064132A2 (en) | 2006-11-17 | 2008-05-29 | Trustees Of Dartmouth College | Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth |
US7714012B2 (en) | 2006-11-17 | 2010-05-11 | Trustees Of Dartmouth University | Synthesis and biological activities of new tricyclic-bis-enones (TBEs) |
US20110112196A1 (en) | 2007-02-08 | 2011-05-12 | Matvey E Lukashev | Nrf2 screening assays and related methods and compositions |
WO2008111497A1 (ja) | 2007-03-08 | 2008-09-18 | Santen Pharmaceutical Co., Ltd. | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 |
WO2008136838A1 (en) | 2007-05-04 | 2008-11-13 | Trustees Of Dartmouth College | Novel amide derivatives of cddo and methods of use thereof |
WO2009023845A2 (en) | 2007-08-15 | 2009-02-19 | The Board Of Regents Of The University Of Texas System | Combination therapy with synthetic triterpenoids and gemcitabine |
US8088824B2 (en) | 2007-08-15 | 2012-01-03 | Reata Pharmaceuticals Inc. | Forms of CDDO methyl ester |
US9012439B2 (en) | 2007-10-29 | 2015-04-21 | University Of Rochester | Use of electrophilic compounds for inducing platelet production or maintaining platelet function |
MX356760B (es) | 2008-01-11 | 2018-06-12 | Dartmouth College | Triterpenoides sinteticos y metodos de uso en el tratamiento de enfermedad. |
US8071632B2 (en) | 2008-04-18 | 2011-12-06 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
WO2009129548A1 (en) | 2008-04-18 | 2009-10-22 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives |
CN102066397B (zh) | 2008-04-18 | 2013-09-11 | 里亚塔医药公司 | 包含抗炎症药效团的化合物以及使用方法 |
US7915402B2 (en) | 2008-04-18 | 2011-03-29 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring |
AU2009237579C1 (en) | 2008-04-18 | 2016-05-12 | Reata Pharmaceuticals Holdings, LLC | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
EP2309860B1 (en) | 2008-07-22 | 2014-01-08 | Trustees of Dartmouth College | Monocyclic cyanoenones and methods of use thereof |
WO2010053817A1 (en) | 2008-11-04 | 2010-05-14 | Trustees Of Dartmouth College | Betulinic acid derivatives and methods of use thereof |
PL3254675T3 (pl) | 2009-02-13 | 2019-09-30 | Reata Pharmaceuticals, Inc. | Kompozycje doustne o opóźnionym uwalnianiu, zawierające amorficzny cddo-me |
RU2401273C1 (ru) | 2009-03-30 | 2010-10-10 | Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) (статус государственного учреждения) | Противоопухолевое средство тритерпеновой природы, полученное путем модификации глицирретовой кислоты |
PL2558105T3 (pl) | 2010-04-12 | 2020-04-30 | Reata Pharmaceuticals, Inc. | Metylowany bardoksolon do leczenia otyłości |
BR112013019419A2 (pt) | 2011-01-31 | 2019-12-03 | Bristol-Myers Squibb Company | triterpenoides modificados por c-17 e c-3 com atividade inibitória de maturação de hiv |
EA026847B1 (ru) | 2011-03-11 | 2017-05-31 | Рита Фармасьютикалз, Инк. | C4-монометилтритерпеноидные производные и способы их применения |
CN208692323U (zh) | 2018-08-13 | 2019-04-05 | 深圳市优维尔科技有限公司 | 一种抽吸装置 |
US11133308B2 (en) | 2019-05-03 | 2021-09-28 | International Business Machines Corporation | Uniform work function metal recess for vertical transistor complementary metal oxide semiconductor technology |
-
2009
- 2009-04-20 WO PCT/US2009/041176 patent/WO2009129548A1/en active Application Filing
- 2009-04-20 CA CA2721666A patent/CA2721666C/en active Active
- 2009-04-20 DK DK09732769.6T patent/DK2271658T3/en active
- 2009-04-20 KR KR20107025718A patent/KR20110010611A/ko not_active Application Discontinuation
- 2009-04-20 TW TW098113097A patent/TWI584808B/zh active
- 2009-04-20 PL PL09732769T patent/PL2271658T3/pl unknown
- 2009-04-20 US US12/426,832 patent/US7943778B2/en active Active
- 2009-04-20 ES ES09732769.6T patent/ES2613964T3/es active Active
- 2009-04-20 EA EA201001554A patent/EA020156B1/ru unknown
- 2009-04-20 RS RS20170078A patent/RS55631B1/sr unknown
- 2009-04-20 JP JP2011505260A patent/JP5588966B2/ja active Active
- 2009-04-20 LT LTEP09732769.6T patent/LT2271658T/lt unknown
- 2009-04-20 MX MX2010011439A patent/MX2010011439A/es active IP Right Grant
- 2009-04-20 HU HUE09732769A patent/HUE033288T2/en unknown
- 2009-04-20 SI SI200931602A patent/SI2271658T1/sl unknown
- 2009-04-20 PT PT97327696T patent/PT2271658T/pt unknown
- 2009-04-20 AU AU2009237581A patent/AU2009237581C1/en active Active
- 2009-04-20 BR BRPI0911422A patent/BRPI0911422B8/pt active IP Right Grant
- 2009-04-20 KR KR1020167029864A patent/KR101782020B1/ko active IP Right Grant
- 2009-04-20 NZ NZ58871109A patent/NZ588711A/xx unknown
- 2009-04-20 ME MEP-2017-27A patent/ME02751B/me unknown
- 2009-04-20 EP EP09732769.6A patent/EP2271658B1/en active Active
- 2009-04-20 CN CN201410370080.XA patent/CN104250280A/zh active Pending
- 2009-04-20 CN CN200980123243.1A patent/CN102066398B/zh active Active
-
2010
- 2010-10-17 IL IL208759A patent/IL208759B/en active IP Right Grant
- 2010-10-25 ZA ZA2010/07589A patent/ZA201007589B/en unknown
- 2010-11-18 CO CO10144468A patent/CO6311107A2/es active IP Right Grant
-
2011
- 2011-02-23 US US13/033,475 patent/US8394967B2/en active Active
- 2011-07-04 HK HK11106765A patent/HK1152713A1/xx unknown
-
2013
- 2013-01-14 US US13/741,072 patent/US9249089B2/en active Active
-
2014
- 2014-07-28 JP JP2014152564A patent/JP2015028019A/ja active Pending
- 2014-09-11 AU AU2014224098A patent/AU2014224098A1/en not_active Abandoned
-
2015
- 2015-05-07 HK HK15104353.6A patent/HK1203968A1/xx unknown
-
2017
- 2017-01-23 CY CY20171100090T patent/CY1118475T1/el unknown
- 2017-01-23 HR HRP20170102TT patent/HRP20170102T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20170102T1 (hr) | Antioksidantni modulatori upale: c17-homologiranih derivata oleanolne kiseline | |
HRP20220797T1 (hr) | Spojevi | |
DE60132011T2 (de) | Nitroderivate als arzneimittel für auf entzündungen beruhende erkrankungen | |
WO2011160267A1 (zh) | 取代苯酚的羟基酸酯化合物、制备方法及在药物中的应用 | |
HRP20140195T1 (hr) | Supstituirani derivati triazolopiridazina | |
CA2615466A1 (en) | Benzofused five-membered heterocycles as inhibitors of catechol-o-methyltransferase (comt) enzyme | |
EP2443125A2 (en) | Camptothecin derivatives | |
CA3122989A1 (en) | Cromolyn esters and uses thereof | |
DE4126662A1 (de) | Neue 3,5-di-tert.butyl-4-hydroxyphenyl-derivate, verfahren zu ihrer herstellung und arzneimittel | |
BR112021005941A2 (pt) | pró-fármaco de nitroxolina e uso do mesmo | |
ES2616809T3 (es) | Derivados de pirimidina-carboxamida | |
AU2017372251A1 (en) | Water-soluble allopregnenolone derivative and use thereof | |
Zarghi et al. | Synthesis and calcium antagonist activity of 1, 4-dihydropyridines containing phenylaminoimidazolyl substituents | |
WO2021008173A1 (zh) | 一种螺(3,3'-异丙基吡咯烷氧化吲哚)类肝x受体调节剂及其制备方法和应用 | |
DD273633A5 (de) | Verfahren zur herstellung von 4-aminopyridin-derivaten | |
ES2742412T3 (es) | Proceso de síntesis para la preparación de derivados del ácido 2-furoico | |
WO2022146914A1 (en) | Cromolyn derivatives and uses thereof | |
CH679583A5 (hr) | ||
SK13852000A3 (sk) | Beta-karbolnov derivty s hypnotickmi inkami, ich prprava a pouitie ako lieebnch prpravkov | |
DE10210195A1 (de) | Derivate von Aza-Spiroverbindungen | |
JP4024992B2 (ja) | ポリナルブフィン誘導体及びそれを製造するための方法 | |
EP0234516B1 (de) | 1,6-Naphthyridin-Derivate,Verfahren zu deren Herstellung und diese enthaltende Arzneimittel zur Behandlung von Gefässerkrankungen | |
FR2874923A1 (fr) | Application a titre de medicaments de derives du 3, 5-seco-4-nor-cholestane, compositions pharmaceutiques les renfermant, nouveaux derives et leur procede de preparation | |
BRPI0607547A2 (pt) | uso de compostos, compostos, composição farmacêutica, e, método de preparar a mesma | |
EP1485352B1 (de) | Aza-spiroverbindungen zur behandlug von schmerzen |